Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.

Kishimoto T, Sanghani S, Russ MJ, Marsh AN, Morris J, Basu S, John M, Kane JM.

Int Clin Psychopharmacol. 2017 May;32(3):161-168. doi: 10.1097/YIC.0000000000000165.

PMID:
28181959
2.

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V.

Ther Adv Psychopharmacol. 2014 Oct;4(5):198-219. doi: 10.1177/2045125314540297. Review.

3.

Antipsychotic combinations for schizophrenia.

Maayan N, Soares-Weiser K, Xia J, Adams CE.

Cochrane Database Syst Rev. 2011;(2). pii: CD009005. Update in: Cochrane Database Syst Rev. 2017 Jun 28;6:CD009005.

4.

Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.

Sun F, Stock EM, Copeland LA, Zeber JE, Ahmedani BK, Morissette SB.

Am J Health Syst Pharm. 2014 May 1;71(9):728-38. doi: 10.2146/ajhp130471.

5.

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.

Citrome L, Weiden PJ, McEvoy JP, Correll CU, Cucchiaro J, Hsu J, Loebel A.

CNS Spectr. 2014 Aug;19(4):330-9. doi: 10.1017/S109285291300093X. Epub 2013 Dec 16.

6.

A retrospective study of antipsychotic drug switching in a pediatric population.

Linton D, Procyshyn RM, Elbe D, Lee LH, Barr AM.

BMC Psychiatry. 2013 Oct 8;13:248. doi: 10.1186/1471-244X-13-248.

7.

The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries.

Horvitz-Lennon M, Donohue JM, Lave JR, AlegrĂ­a M, Normand SL.

Psychiatr Serv. 2013 Mar 1;64(3):230-7. doi: 10.1176/appi.ps.201200041.

8.

Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Correll CU, Gallego JA.

Psychiatr Clin North Am. 2012 Sep;35(3):661-81. doi: 10.1016/j.psc.2012.06.007. Epub 2012 Jul 24. Review.

9.

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis.

Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M, Conley RR.

Neuropsychiatr Dis Treat. 2012;8:259-66. doi: 10.2147/NDT.S25662. Epub 2012 Jun 18.

10.

Race and long-acting antipsychotic prescription at a community mental health center: a retrospective chart review.

Aggarwal NK, Rosenheck RA, Woods SW, Sernyak MJ.

J Clin Psychiatry. 2012 Apr;73(4):513-7. doi: 10.4088/JCP.11m07161.

11.

Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU.

Schizophr Res. 2012 Jun;138(1):18-28. doi: 10.1016/j.schres.2012.03.018. Epub 2012 Apr 24. Review.

12.

Antipsychotic treatment among youth in foster care.

Dosreis S, Yoon Y, Rubin DM, Riddle MA, Noll E, Rothbard A.

Pediatrics. 2011 Dec;128(6):e1459-66. doi: 10.1542/peds.2010-2970. Epub 2011 Nov 21.

13.

The effect of ethnicity on prescribing practice and treatment outcome in inpatients suffering from schizophrenia in Greece.

Douzenis A, Apostolopoulos A, Seretis D, Rizos EN, Christodoulou C, Lykouras L.

BMC Psychiatry. 2011 Apr 20;11:66. doi: 10.1186/1471-244X-11-66.

14.

Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI.

Young AS, Niv N, Chinman M, Dixon L, Eisen SV, Fischer EP, Smith J, Valenstein M, Marder SR, Owen RR.

Community Ment Health J. 2011 Apr;47(2):123-35. doi: 10.1007/s10597-010-9328-y. Epub 2010 Jul 25.

15.

Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.

Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM.

J Clin Psychiatry. 2010 Apr;71(4):463-74. doi: 10.4088/JCP.07m03890yel. Epub 2010 Feb 9.

16.

A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Honer WG, Procyshyn RM, Chen EY, MacEwan GW, Barr AM.

J Psychiatry Neurosci. 2009 Nov;34(6):433-42. Review.

17.

Racial and ethnic disparities in the treatment of a Medicaid population with schizophrenia.

Horvitz-Lennon M, McGuire TG, Alegria M, Frank RG.

Health Serv Res. 2009 Dec;44(6):2106-22. doi: 10.1111/j.1475-6773.2009.01041.x. Epub 2009 Sep 24.

18.

High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies.

Sim K, Su HC, Fujii S, Yang SY, Chong MY, Ungvari G, Si T, He YL, Chung EK, Chan YH, Shinfuku N, Kua EH, Tan CH, Sartorius N.

Br J Clin Pharmacol. 2009 Jan;67(1):110-7. doi: 10.1111/j.1365-2125.2008.03304.x.

19.

Cost of antipsychotic polypharmacy in the treatment of schizophrenia.

Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM.

BMC Psychiatry. 2008 Apr 4;8:19. doi: 10.1186/1471-244X-8-19.

20.

Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.

Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC.

Psychiatr Serv. 2007 Apr;58(4):489-95.

Supplemental Content

Support Center